赫赛汀与泰索帝序贯联合应用对乳腺癌细胞抑制作用的研究  

Inhibitory effect of combined herceptin and docetaxel in different sequence on human breast cancer cells in vitro

作　　者：吴志勇[1] 焦顺昌[1] 彭亮[1] 

机构地区：[1]中国人民解放军总医院肿瘤内科,北京100853

出　　处：《现代肿瘤医学》2007年第3期329-332,共4页Journal of Modern Oncology

基　　金：解放军总医院与上海罗氏制药公司合作项目(编号:03YH006)

摘　　要：目的探讨赫赛汀与泰索帝联合作用于乳腺癌时,抑制作用最强的序贯方式;赫赛汀对于泰索帝作用的影响及其机制。方法利用MTT法及流式细胞技术测定单纯赫赛汀组、单纯化疗组以及不同序贯方式赫赛汀结合化疗组对人乳腺癌细胞(MDA-MB543)的抑制率及细胞周期的影响。结果赫赛汀作用18h后应用泰索帝,两药联合作用对乳腺癌细胞的抑制率最强(53.12%),优于单纯化疗组(41.55%)及其他序贯方式作用组,特别是化疗后应用赫赛汀组(P<0.01);此时泰索帝抑制率最高为(46.15%)。此种序贯方式与其他序贯方式相比可更有效地将细胞阻滞在G0/G1和G2/M期。结论赫赛汀应用18h后应用泰索帝,可最大程度增强泰索帝的抑制作用,优于单药及其他序贯方式,且此时两药联合对于肿瘤细胞的抑制作用最强。较其它序贯方式可更有效地将细胞阻滞在G0/G1和G2/M期,影响细胞的生长及凋亡,而发挥协同作用。Objective： To investigate the best consequence of combined treatment with herceptin and docetaxel to the breast cancer in vitro and its mechanism. Methods： Inhibition ratio to human breast cancer cells （ MDA - MB543） of the group of herceptin treatment , chemical treatment with docetaxel and herceptin -chemical combined treatment were assayed by the method of MTT and change of cell cycle by flow cytometry （FCM）. Results： Combined treatment of herceptin with docetaxel 18 h later had got the largest inhibition ratio to breast cancer cells （53.12%） and docetaxel got its largest inhibition ratio to cells（46.15% ） . It was higher than group of docetaxel （41.55%） and the groups of combined treatment with other consequences （ P 〈 0.01 ） . And in this sequence, the cells were apparently arrested in G0/G1 and G2/M phase. Conclusion： Combined treatment of herceptin with docetaxel 18h later had the strongest toxicity to breast cancer cells and herceptin enhanced the toxicity of docetaxel to breast cancer cells best . And this sequence could apparently arrested cells in G0/G1 and G2/M phase , then induce apoptosis.

关 键 词：赫赛汀 泰索帝 化疗 MDA—MB543细胞株 细胞周期 

分 类 号：R737.9[医药卫生—肿瘤]